利妥昔单抗（Rituximab）作为首个获批的抗肿瘤单抗药物，通过靶向CD20抗原显著改善了非霍奇金淋巴瘤患者的预后。将FITC与该单抗结合，不仅保留了其免疫识别能力，更赋予实时成像功能，为肿瘤靶向治疗提供可视化导航。 标记技术优化 FITC通过其异硫氰酸基团 ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. This study aimed to optimize and validate a cationization method for the Fab’ fragment ...

Over 10 days, the porcine liver produces bile and porcine albumin, maintains stable blood flow, and shows no signs of ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Shanghai Henlius Biotech, Inc. (2696) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has valida ...

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

Q4 2024 Management View CEO Ameet Mallik highlighted that 2024 was focused on execution, achieving key milestones, advancing ZYNLONTA, and strengthening the balance sheet. The company completed ...

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on ...